Purespring Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 50

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $106M

  • Investors
  • 6

Purespring Therapeutics General Information

Description

Developer of kidney-targeted gene therapy products intended for the treatment of chronic glomerular kidney diseases, including rare inherited and non-genetic conditions. The company offers a podocyte-focused gene therapy platform that directs vectors to glomerular structures, aims to maintain kidney filtration function, concentrates on modulating complement signalling in the glomeruli through its lead program for IgA nephropathy, and advances additional candidates for monogenic podocyte disorders such as NPHS2 nephropathy and glomerular basement membrane deficiencies, enabling nephrologists healthcare providers researchers and patients to access disease-modifying therapeutic approaches aimed at delaying or preventing progression to end-stage renal disease dialysis or kidney transplant.

Contact Information

Formerly Known As
Syncona Collaboration (S)
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 8 Bloomsbury Street
  • London WC1B 3SR
  • England, United Kingdom
+44 020
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 8 Bloomsbury Street
  • London WC1B 3SR
  • England, United Kingdom
+44 020

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Purespring Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 08-Oct-2024 $106M Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 19-Nov-2020 Completed Pre-Clinical Trials
1. Spin-Off 01-Apr-2020 Completed Startup
To view Purespring Therapeutics’s complete valuation and funding history, request access »

Purespring Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B2
Series B1
Series A 18,500,000 $0.000013 $1.32 $1.32 1x $1.32 13.1%
To view Purespring Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Purespring Therapeutics Patents

Purespring Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202511557-D0 Gene system Inactive 16-Jul-2025
GB-202511174-D0 Methods Pending 10-Jul-2025
GB-202510228-D0 Gene system Pending 26-Jun-2025
GB-202508472-D0 Gene system Pending 30-May-2025
GB-202508471-D0 Vectors Pending 30-May-2025 C12N15/86
To view Purespring Therapeutics’s complete patent history, request access »

Purespring Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Purespring Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
British Business Bank Lender/Debt Provider Minority
Forbion Venture Capital Minority
Gilde Healthcare PE/Buyout Minority
Sofinnova Partners Venture Capital Minority
Syncona Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Purespring Therapeutics FAQs

  • When was Purespring Therapeutics founded?

    Purespring Therapeutics was founded in 2020.

  • Where is Purespring Therapeutics headquartered?

    Purespring Therapeutics is headquartered in London, United Kingdom.

  • What is the size of Purespring Therapeutics?

    Purespring Therapeutics has 50 total employees.

  • What industry is Purespring Therapeutics in?

    Purespring Therapeutics’s primary industry is Drug Discovery.

  • Is Purespring Therapeutics a private or public company?

    Purespring Therapeutics is a Private company.

  • What is the current valuation of Purespring Therapeutics?

    The current valuation of Purespring Therapeutics is .

  • What is Purespring Therapeutics’s current revenue?

    The current revenue for Purespring Therapeutics is .

  • How much funding has Purespring Therapeutics raised over time?

    Purespring Therapeutics has raised $165M.

  • Who are Purespring Therapeutics’s investors?

    British Business Bank, Forbion, Gilde Healthcare, Sofinnova Partners, and Syncona are 5 of 6 investors who have invested in Purespring Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process